Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 302

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 302
---
,805)(27,984)(65,370)(52,423)Other income:Interest income3,456 2,353 10,123 6,051 Other income71 190 419 532 Total other income3,527 2,543 10,542 6,583 Net loss$(20,278)$(25,441)$(54,828)$(45,840)Net loss per share, basic and diluted$(0.46)$(5.67)$(1.43)$(12.81)Weighted-average common shares outstanding, basic and diluted44,255,053 4,485,813 38,387,388 3,579,408 Comprehensive loss:Net loss$(20,278)$(25,441)$(54,828)$(45,840)Unrealized gain on marketable securities237 929 52 773 Total other comprehensive gain237 929 52 773 Comprehensive loss$(20,041)$(24,512)$(54,776)$(45,067)

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-3

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share amounts) 

(Unaudited)

Series SeedSeries ASeries BSeries C Common Stock AdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficitTotalStockholders’DeficitPreferred Stock Preferred StockPreferred Stock Preferred Stock SharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance at December 31, 20233,963,963$13,014 5,704,161$25,235 11,370,621$110,791 —$— 3,050,863$2 $4,515 $— $(119,398)$(114,881)Issuance of Series C Preferred Stock, net of issuance costs of $528—— —— —— 18,628,970181,328 —— — — — — Exercise of common stock options—— —— —— —— 821— 5 — — 5 Vesting of restricted common stock awards—— —— —— —— 51,1851 — — — 1 Stock-based